Calliditas Therapeutics (CALT NASDAQ) stock market data APIs
$39.9757
0(0%)
as of September 27, 2024
Try our APIs with
free plan!
Calliditas Therapeutics Financial Data Overview
Price chart is built with
Anychart
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
Prev. Close
39.9757
Open
39.9757
High
39.9757
Low
39.9757
52 wk Range
40-43
Market Cap
1 097 M
Shares Outstanding
27 017 K
Revenue
1 601 M
EPS
-0.16
Beta
1.457
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Calliditas Therapeutics data using free add-ons & libraries
Get Calliditas Therapeutics Fundamental Data
Calliditas Therapeutics Fundamental data includes:
- Net Revenue: 1 601 M
- EBITDA: -365 368 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-08-13
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Calliditas Therapeutics News
New
3 European Dividend Stocks Yielding Up To 5.1%
Amid recent challenges in the European markets, including concerns over U.S. Federal Reserve independence and geopolitical tensions, the pan-European STOXX Europe 600 Index has seen a notable decline....
Hong Kong tops the US as the go-to IPO venue for Chinese start-ups as funds return to Asia
In the first of a two-part series about Hong Kong's market for initial public offerings, Zhang Shidong and Ao Yulu report that more Chinese companies opted to list in Hong Kong in the first eight mont...
Discover 3 European Dividend Stocks Yielding Up To 6.9%
The European market recently experienced a downturn, with the STOXX Europe 600 Index dropping 2.57% due to dissatisfaction with a trade deal framework between the U.S. and EU, while major indices in F...
Calliditas Therapeutics provides business update ahead of JP Morgan conference
STOCKHOLM, Jan. 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a business update ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
